Skip to main content
Fig. 5 | Journal of Nanobiotechnology

Fig. 5

From: A proof-of-concept study on bioorthogonal-based pretargeting and signal amplify radiotheranostic strategy

Fig. 5

Ex vivo biodistribution of [177Lu]Lu-PSMA-Tz in 22Rv1 tumor-bearing mice (n = 4) at 48 h p.i. without (Group i) (A) or with (Group ii) (B) the pre-injection of Pd@Au-PEG-TCO. The tumor-to-muscle (T/M), tumor-to-liver (T/L), and tumor-to-kidney (T/K) ratios of Group i (C) and Group ii (D) were calculated from the results of biodistribution. E The AUCs of tumor uptake for groups i and ii were calculated and compared

Back to article page